Latest Secondary Market News

Australian Bond Exchange Holdings improved revenue, reduced its annual loss and sharply cut operating cash outflow in FY2026. Yet with only A$249,000 in cash, net liabilities of A$1.43 million and A$2 million of convertible notes maturing from April 2027, the turnaround remains financially fragile.

Latrobe Magnesium has secured A$8.5 million in equity funding to complete its Latrobe Valley demonstration plant and advance a proposed South Carolina magnesium project. The raising gives the company near-term funding certainty, but also brings further dilution and leaves the larger US development dependent on future capital.

AI Private Opportunities Trust (ASX: AIX) has completed its first reporting period, raising $267 million and beginning deployment into high-profile private AI companies including ByteDance and Databricks.

Island Pharmaceuticals has commissioned a second manufacturing run of its antiviral Galidesivir, aiming to stockpile up to 800 treatment courses by late 2026 to support rapid response to the fast-spreading Bundibugyo Ebola outbreak and biodefence efforts.

Noumi Limited lifted FY26 revenue by 8.8% and adjusted operating EBITDA by 7.6%, driven by Dairy & Nutritionals' strong earnings and strategic investments in Plant-based Milks. The company faces refinancing uncertainty with $610 million convertible notes maturing in May 2027, prompting a proposed acquisition by majority shareholder Arrovest.

Global X Metal Securities Australia Limited has issued a prospectus for five classes of securities tracking gold, silver, platinum, palladium, and a precious metals basket. The securities are physically backed, traded on ASX under AQUA Rules, and managed by JPMorgan Chase Bank.

Global X Metal Securities Australia Limited has refreshed its prospectus for five classes of precious metals securities, maintaining physical bullion backing and ASX AQUA listing, with detailed disclosures on structure, fees, risks, and tax implications.

Westpac has completed the $15.4 billion sale of its RAMS mortgage portfolio to a consortium including Pepper Money, KKR, and PIMCO, lifting its capital ratio and simplifying operations.

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for its suite of 27 ETFs on the ASX, updating investment strategies, fee structures, risk factors, and operational details.

Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.

Summerset Group maintained stable new sales in Q2 2026 with a notable 26% jump in resales, while prudently reducing its New Zealand build rate in response to economic uncertainty.

Vanguard Investments Australia has released estimated distribution amounts for 34 ETFs, covering a broad spectrum of asset classes, with payments scheduled for mid-July 2026.